DK141682B - Fremgangsmåde til ultrafiltrering af opløsninger, der indeholder geldannende dispergerede partikler eller geldannende makromolekyler. - Google Patents

Fremgangsmåde til ultrafiltrering af opløsninger, der indeholder geldannende dispergerede partikler eller geldannende makromolekyler. Download PDF

Info

Publication number
DK141682B
DK141682B DK53170AA DK53170A DK141682B DK 141682 B DK141682 B DK 141682B DK 53170A A DK53170A A DK 53170AA DK 53170 A DK53170 A DK 53170A DK 141682 B DK141682 B DK 141682B
Authority
DK
Denmark
Prior art keywords
membrane
gelling
ultrafiltration
macromolecules
solute
Prior art date
Application number
DK53170AA
Other languages
Danish (da)
English (en)
Other versions
DK141682C (enExample
Inventor
Heinrich Strathmann
Richard William Baker
Original Assignee
Amicon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicon Corp filed Critical Amicon Corp
Publication of DK141682B publication Critical patent/DK141682B/da
Application granted granted Critical
Publication of DK141682C publication Critical patent/DK141682C/da

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/18—Apparatus therefor

Landscapes

  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
DK53170AA 1969-02-05 1970-02-03 Fremgangsmåde til ultrafiltrering af opløsninger, der indeholder geldannende dispergerede partikler eller geldannende makromolekyler. DK141682B (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79692869A 1969-02-05 1969-02-05
US79692869 1969-02-05

Publications (2)

Publication Number Publication Date
DK141682B true DK141682B (da) 1980-05-27
DK141682C DK141682C (enExample) 1980-10-20

Family

ID=25169415

Family Applications (1)

Application Number Title Priority Date Filing Date
DK53170AA DK141682B (da) 1969-02-05 1970-02-03 Fremgangsmåde til ultrafiltrering af opløsninger, der indeholder geldannende dispergerede partikler eller geldannende makromolekyler.

Country Status (10)

Country Link
US (1) US3541005A (enExample)
JP (1) JPS4931431B1 (enExample)
BE (1) BE745442A (enExample)
DE (1) DE2005260A1 (enExample)
DK (1) DK141682B (enExample)
FR (1) FR2033961A5 (enExample)
GB (1) GB1307331A (enExample)
NL (1) NL7001662A (enExample)
SE (1) SE350702B (enExample)
ZA (1) ZA70548B (enExample)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2254860C3 (de) * 1971-11-26 1984-03-29 Heinrich Frings Gmbh & Co Kg, 5300 Bonn Ultrafiltrationsverfahren für Flüssigkeiten, die Mikroorganismen, Makromoleküle oder andere kleine Feststoffteilchen enthalten
JPS568476U (enExample) * 1979-06-30 1981-01-24
JPS56110625A (en) * 1980-02-05 1981-09-01 Takeda Chem Ind Ltd Separating method of blood plasma and apparatus for the same
US4735726A (en) * 1981-07-22 1988-04-05 E. I. Du Pont De Nemours And Company Plasmapheresis by reciprocatory pulsatile filtration
US4640776A (en) * 1982-02-16 1987-02-03 E. I. Du Pont De Nemours And Company Plasmapheresis filtration module having pressure balancing and sealing means
US4639317A (en) * 1982-02-16 1987-01-27 E. I. Du Pont De Nemours And Company Plasmapheresis filtration module having improved sealing means
US4636312A (en) * 1982-02-16 1987-01-13 E. I. Du Pont De Nemours And Company Plasmapheresis filtration module having improved end plate
US4769150A (en) * 1982-02-16 1988-09-06 E. I. Du Pont De Nemours And Company Method and apparatus for plasmapheresis by reciprocatory pulsatile filtration
DE3525668A1 (de) * 1984-10-31 1986-05-07 Kernforschungsanlage Jülich GmbH, 5170 Jülich Verfahren zur bestimmung des gehaltes an in einem loesungsmittel geloesten stoffen
US4693886A (en) * 1985-04-22 1987-09-15 Alza Corporation Osmotic device with inert core
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5340590A (en) * 1987-06-25 1994-08-23 Alza Corporation Delivery system with bilayer osmotic engine
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US4969884A (en) * 1988-12-28 1990-11-13 Alza Corporation Osmotically driven syringe
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5035897A (en) * 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs
US4986918A (en) * 1989-11-08 1991-01-22 Romicon Inc. Membrane separation system and method of operation
US5030216A (en) * 1989-12-15 1991-07-09 Alza Corporation Osmotically driven syringe
US5474785A (en) * 1990-01-24 1995-12-12 Alza Corporation Delivery system comprising means for controlling internal pressure
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5240713A (en) * 1991-09-27 1993-08-31 Alza Corporation Dual rate agent delivery device
US5200194A (en) * 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US6287598B1 (en) 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy
US5540665A (en) * 1994-01-31 1996-07-30 Alza Corporation Gas driven dispensing device and gas generating engine therefor
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
EP0749038A1 (en) 1995-06-16 1996-12-18 Minnesota Mining And Manufacturing Company Light-sensitive photographic materials comprising tabular silver halide grains and azodicarbonamide derivatives
US6110499A (en) * 1997-07-24 2000-08-29 Alza Corporation Phenytoin therapy
US6514530B2 (en) 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
PT1035834E (pt) 1997-12-05 2002-09-30 Alza Corp Forma de dosagem osmotica que compreende primeiro e segundo revestimentos
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
DK1685839T3 (da) 1997-12-22 2013-06-24 Euro Celtique Sa Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
GB9822854D0 (en) 1998-10-21 1998-12-16 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
EP1652516A3 (en) 1998-11-02 2006-05-17 ALZA Corporation Osmotic controlled delivery of active agents
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6319510B1 (en) 1999-04-20 2001-11-20 Alayne Yates Gum pad for delivery of medication to mucosal tissues
KR100738276B1 (ko) * 1999-12-09 2007-07-12 알자 코포레이션 항바이러스성 약제
EP2283829A1 (en) 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US7943173B2 (en) 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
EP1492509A1 (en) * 2001-12-18 2005-01-05 ALZA Corporation Dosage form providing time-varying patterns of drug delivery
CA2471081A1 (en) * 2001-12-19 2003-07-03 Alza Corporation Formulation & dosage form for the controlled delivery of therapeutic agents
CN1606432A (zh) * 2001-12-19 2005-04-13 阿尔扎公司 用于增加亲水性大分子的口服生物利用度的制剂和剂型
CA2478515C (en) * 2002-04-05 2010-09-28 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
DE60325715D1 (de) * 2002-04-29 2009-02-26 Alza Corp Methoden und darreichungsformen zur kontrollierten freisetzung von oxykodon
RU2004134728A (ru) * 2002-05-31 2005-06-10 Алза Корпорейшн (Us) Дозированные формы и композиции для осмотической доставки различных дозировок оксикодона
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
NZ537543A (en) * 2002-07-29 2007-08-31 Alza Corp Formulations and high dose osmotic dosage forms for controlled delivery of topiramate
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
ES2286486T3 (es) * 2002-12-17 2007-12-01 ABBOTT GMBH & CO. KG Formulacion que comprende acido fenofibrico, una sal o un derivado fisiologicamente aceptables del mismo.
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
JP2006522016A (ja) * 2003-01-14 2006-09-28 アルザ・コーポレーシヨン 改変された粘度の層を用いる方法および投薬形態物
CA2515641A1 (en) * 2003-02-11 2004-08-26 Alza Corporation Methods and dosage forms with modified layer geometry
EP1905435A3 (en) 2003-03-11 2008-05-14 Euro-Celtique S.A. Titration dosing regimen for controlled release tramadol
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
EP1643946A2 (en) * 2003-06-20 2006-04-12 Viral Genomix, Inc. Compositions for and methods for treating hiv
JP2007501248A (ja) * 2003-08-06 2007-01-25 アルザ・コーポレーシヨン 増進した分散調合物による長時間にわたるトピラメートの均一送達
US20050136108A1 (en) * 2003-08-22 2005-06-23 Yam Noymi V. Stepwise delivery of topiramate over prolonged period of time
WO2005020959A2 (en) * 2003-09-02 2005-03-10 Alza Corporation Novel drug compositions and dosage forms of topiramate
EP1663229B1 (en) 2003-09-25 2010-04-14 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
JP2007506775A (ja) * 2003-09-26 2007-03-22 アルザ・コーポレーシヨン 漸増する放出速度を表す制御放出製剤
US8246986B2 (en) 2003-09-26 2012-08-21 Alza Corporation Drug coating providing high drug loading
CA2540056C (en) * 2003-09-26 2015-03-24 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
JP2007511519A (ja) * 2003-11-14 2007-05-10 アルザ・コーポレーシヨン 液状投薬形態物におけるトピラメートの制御放出
US20050158365A1 (en) * 2003-12-22 2005-07-21 David Watson Drug delivery device with mechanical locking mechanism
US20050136095A1 (en) * 2003-12-22 2005-06-23 Brian Levy Drug delivery device with suture ring
WO2005063206A1 (en) * 2003-12-23 2005-07-14 Alza Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
CA2551815A1 (en) * 2003-12-29 2005-07-21 Alza Corporation Novel drug compositions and dosage forms
MXPA06007510A (es) * 2003-12-29 2009-06-10 Johnson & Johnson Composiciones de farmaco y formas de dosis novedosas de topiramato.
WO2006079550A2 (en) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
TWI483944B (zh) * 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US20060009425A1 (en) * 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1765292B1 (en) 2004-06-12 2017-10-04 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
CA2571554A1 (en) * 2004-06-28 2006-01-19 Alza Corporation A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device
US20050287214A1 (en) * 2004-06-28 2005-12-29 Ayer Atul D Squeeze controlled oral dosage form
WO2006007323A2 (en) * 2004-06-28 2006-01-19 Alza Corporation Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
EP1791520A2 (en) * 2004-08-19 2007-06-06 Alza Corporation Controlled release nanoparticle active agent formulation dosage forms and methods
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US20060067980A1 (en) * 2004-09-30 2006-03-30 Bausch & Lomb Incorporated Capsule for encasing tablets for surgical insertion into the human body
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
DK2486942T3 (en) 2004-11-24 2019-01-28 Meda Pharmaceuticals Inc COMPOSITIONS CONTAINING AZELASTINE AND PROCEDURES FOR USING IT
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US20060134162A1 (en) * 2004-12-16 2006-06-22 Larson Christopher W Methods for fabricating a drug delivery device
ATE413864T1 (de) * 2005-01-27 2008-11-15 Alza Corp Orale osmotische darreichungsform mit membran mit hoher flussdichte
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
US20060233882A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Osmotic dosage form
CA2605180A1 (en) * 2005-04-19 2006-10-26 Alza Corporation Controlled delivery dosage form of tramadol and gabapentin
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
WO2008084698A1 (ja) 2006-12-28 2008-07-17 Astellas Pharma Inc. タクロリムス徐放性医薬組成物
US8524749B2 (en) * 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
WO2008109018A1 (en) * 2007-03-02 2008-09-12 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
WO2008151071A1 (en) * 2007-05-30 2008-12-11 Neos Therapeutics, Lp Modifying drug release in suspensions of ionic resin systems
US20090087484A1 (en) * 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
DK3045043T3 (da) 2009-02-26 2020-08-03 Relmada Therapeutics Inc Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2011122524A1 (ja) 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
EP2826467B1 (en) 2010-12-22 2017-08-02 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
CA2879268C (en) 2012-07-16 2018-05-08 Rhodes Technologies Process for improved opioid synthesis
SG11201407988UA (en) 2012-07-16 2015-01-29 Rhodes Technologies Process for improved opioid synthesis
MX393493B (es) 2012-11-02 2025-03-21 Murray & Poole Entpr Ltd Tratamiento o prevención de eventos cardiovasculares.
CN105120846B (zh) 2013-02-05 2019-10-18 普渡制药公司 抗篡改的药物制剂
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
AU2014255434B2 (en) 2013-04-16 2018-11-08 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
KR20160003128A (ko) 2013-04-30 2016-01-08 애브비 인코포레이티드 아트라센탄을 사용하는 지질 프로파일을 개선시키기 위한 방법
KR20180037074A (ko) 2013-07-23 2018-04-10 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
MX379406B (es) 2014-01-15 2025-03-11 Rhodes Tech Proceso para la síntesis mejorada de oximorfona.
AU2015207733A1 (en) 2014-01-15 2016-07-14 Rhodes Technologies Process for improved oxycodone synthesis
WO2016132217A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Method of improving gaba-b receptor agonist therapy
EP3061501A1 (en) 2015-02-27 2016-08-31 Rottapharm Ltd. Composition for the treatment of acne
EP3283063A1 (en) 2015-04-17 2018-02-21 Murray And Poole Enterprises Limited Colchicine salicylate and uses thereof
EP3117825A1 (en) 2015-07-16 2017-01-18 Rottapharm S.p.A. Oral formulation comprising berberine and morus alba extract
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
CN111954524A (zh) 2018-02-02 2020-11-17 默里和普尔企业有限公司 秋水仙碱抑制肿瘤生长和转移的用途
WO2021029020A1 (ja) 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物
WO2021089715A1 (en) 2019-11-06 2021-05-14 Murray And Poole Enterprises, Ltd. Use of colchicine in the treatment and prevention of lung cancer
US12599598B2 (en) 2020-06-10 2026-04-14 Auspex Pharmaceuticals Llc Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
EP4153136B1 (en) 2020-06-10 2024-01-10 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
IL317235A (en) 2022-06-08 2025-01-01 Auspex Pharmaceuticals Inc Osmotic dosage forms comprising ditetrabenzene and methods of using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3211645A (en) * 1962-07-17 1965-10-12 Technicon Instr Method and apparatus for filtering sanguineous liquid streams
US3305097A (en) * 1963-05-27 1967-02-21 Scientific Industries High pressure peristaltic pump for separation apparatus

Also Published As

Publication number Publication date
SE350702B (enExample) 1972-11-06
DK141682C (enExample) 1980-10-20
FR2033961A5 (enExample) 1970-12-04
US3541005A (en) 1970-11-17
BE745442A (fr) 1970-07-16
GB1307331A (en) 1973-02-21
ZA70548B (en) 1971-08-25
NL7001662A (enExample) 1970-08-07
DE2005260A1 (de) 1970-10-29
JPS4931431B1 (enExample) 1974-08-21

Similar Documents

Publication Publication Date Title
US3541005A (en) Continuous ultrafiltration of macromolecular solutions
Drioli et al. Membrane distillataion in the treatment of aqueous solutions
Riley et al. Preparation of ultrathin reverse osmosis membranes and the attainment of theoretical salt rejection
Strathmann Membrane separation processes
US5098575A (en) Method and apparatus for processing liquid solutions of suspensions particularly useful in the desalination of saline water
US3526588A (en) Macromolecular fractionation process
Goldsmith Macromolecular ultrafiltration with microporous membranes
Nabetani et al. Effects of osmotic pressure and adsorption on ultrafiltration of ovalbumin
US4781837A (en) Method of performing osmetic distillation
US3133137A (en) High flow porous membranes for separating water from saline solutions
US3133132A (en) High flow porous membranes for separating water from saline solutions
Michaels et al. Ultrafiltration
Koops et al. Separation of linear hydrocarbons and carboxylic acids from ethanol and hexane solutions by reverse osmosis
Onsekizoglu Bagci Potential of membrane distillation for production of high quality fruit juice concentrate
Almazán et al. Nanofiltration of glucose: Analysis of parameters and membrane characterization
CHERYAN Mass transfer characteristics of hollow fiber ultrafiltration of soy protein systems
Racz et al. Mass transfer, fluid flow and membrane properties in flat and corrugated plate hyperfiltration modules
Gupta et al. Characterization of nanofiltration and reverse osmosis membrane performance for aqueous salt solutions using irreversible thermodynamics
US3250701A (en) Stabilization of desalination membranes
Fernandez et al. Cross flow filtration of RNA extracts by hollow fiber membrane
Tomaszewska Membrane distillation
Belhocine et al. Optimization of plasma proteins concentration by ultrafiltration
Shalini et al. Forward osmosis membrane concentration of raw sugarcane juice
EP2205710A1 (en) Dewaxing process
Gabino et al. Evaluation of the cleaning of a new hydrophobic membrane for osmotic evaporation